Loading...

We've got a brand new version of Simply Wall St! Try it out

PharmaEngine

GTSM:4162
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4162
GTSM
NT$11B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs to treat cancer diseases in Taiwan. The last earnings update was 90 days ago. More info.


Add to Portfolio Compare Print
4162 Share Price and Events
7 Day Returns
-5.5%
GTSM:4162
-1%
TW Biotechs
1.4%
TW Market
1 Year Returns
-30.4%
GTSM:4162
-9.6%
TW Biotechs
17.7%
TW Market
4162 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
PharmaEngine (4162) -5.5% -1.4% 5.6% -30.4% -58.2% -55.5%
TW Biotechs -1% -2.6% -4.5% -9.6% -39.9% -41.4%
TW Market 1.4% 6% 9.8% 17.7% 27.6% 27.7%
1 Year Return vs Industry and Market
  • 4162 underperformed the Biotechs industry which returned -9.6% over the past year.
  • 4162 underperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
4162
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for PharmaEngine's competitors could be found in our database.

4162 Value

 Is PharmaEngine undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of PharmaEngine to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for PharmaEngine.

GTSM:4162 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-06-30) in TWD NT$ 2.6549825
Payout Ratio Company Filings (2019-06-30) 6076.8%
Discount Rate (Cost of Equity) See below 11%
Perpetual Growth Rate 10-Year TW Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:4162
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.28
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.278 (1 + (1- 20%) (0.1%))
1.392
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.39
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.392 * 5.96%)
11.03%

Discounted Cash Flow Calculation for GTSM:4162 using Dividend Discount Model Model

The calculations below outline how an intrinsic value for PharmaEngine is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

GTSM:4162 Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= NT$2.65 / (11.03% - 2.73%)
NT$32
GTSM:4162 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$32.00
Current discount Discount to share price of NT$71.70
= -1 x (NT$71.70 - NT$32.00) / NT$32.00
-124%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of PharmaEngine is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for PharmaEngine's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are PharmaEngine's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:4162 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in TWD NT$1.12
GTSM:4162 Share Price ** GTSM (2019-11-11) in TWD NT$71.7
Taiwan, Province of China Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 41.22x
Taiwan, Province of China Market PE Ratio Median Figure of 1,438 Publicly-Listed Companies 16.62x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of PharmaEngine.

GTSM:4162 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:4162 Share Price ÷ EPS (both in TWD)

= 71.7 ÷ 1.12

63.93x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PharmaEngine is overvalued based on earnings compared to the TW Biotechs industry average.
  • PharmaEngine is overvalued based on earnings compared to the Taiwan, Province of China market.
Price based on expected Growth
Does PharmaEngine's expected growth come at a high price?
Raw Data
GTSM:4162 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 63.93x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Asia Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.61x
Taiwan, Province of China Market PEG Ratio Median Figure of 244 Publicly-Listed Companies 1.14x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for PharmaEngine, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on PharmaEngine's assets?
Raw Data
GTSM:4162 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in TWD NT$23.98
GTSM:4162 Share Price * GTSM (2019-11-11) in TWD NT$71.7
Taiwan, Province of China Biotechs Industry PB Ratio Median Figure of 40 Publicly-Listed Biotechs Companies 3.4x
Taiwan, Province of China Market PB Ratio Median Figure of 1,939 Publicly-Listed Companies 1.46x
GTSM:4162 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:4162 Share Price ÷ Book Value per Share (both in TWD)

= 71.7 ÷ 23.98

2.99x

* Primary Listing of PharmaEngine.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PharmaEngine is good value based on assets compared to the TW Biotechs industry average.
X
Value checks
We assess PharmaEngine's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. PharmaEngine has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

4162 Future Performance

 How is PharmaEngine expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
149.5%
Expected annual growth in earnings per share.
Earnings growth vs Low Risk Savings
Is PharmaEngine expected to grow at an attractive rate?
  • PharmaEngine's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • PharmaEngine's earnings growth is expected to exceed the Taiwan, Province of China market average.
  • Unable to compare PharmaEngine's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:4162 Future Growth Rates Data Sources
Data Point Source Value (per year)
GTSM:4162 Future Earnings per Share Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 149.5%
Taiwan, Province of China Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 65.2%
Taiwan, Province of China Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 60.6%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.3%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 7.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:4162 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:4162 Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31 332 100 1
2019-11-11
GTSM:4162 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-06-30 375 153 164
2019-03-31 338 95 206
2018-12-31 293 745 129
2018-09-30 1,000 675 647
2018-06-30 890 569 569
2018-03-31 877 496 463
2017-12-31 854 -339 387
2017-09-30 875 465 452
2017-06-30 849 406 364
2017-03-31 1,144 763 607
2016-12-31 1,135 870 690
2016-09-30 330 63 42

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • PharmaEngine's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if PharmaEngine is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:4162 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from PharmaEngine Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4162 Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31 6.80 6.80 6.80 1.00
2019-12-31 0.68 0.68 0.68 1.00
2019-11-11
GTSM:4162 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-06-30 1.12
2019-03-31 1.40
2018-12-31 0.88
2018-09-30 4.40
2018-06-30 3.87
2018-03-31 3.15
2017-12-31 2.63
2017-09-30 3.07
2017-06-30 2.48
2017-03-31 4.14
2016-12-31 4.71
2016-09-30 0.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if PharmaEngine will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess PharmaEngine's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
PharmaEngine has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

4162 Past Performance

  How has PharmaEngine performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare PharmaEngine's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • PharmaEngine's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • PharmaEngine's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • PharmaEngine's 1-year earnings growth is negative, it can't be compared to the TW Biotechs industry average.
Earnings and Revenue History
PharmaEngine's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from PharmaEngine Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4162 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 374.92 164.19 118.93 135.96
2019-03-31 337.53 205.70 111.88 126.08
2018-12-31 293.43 129.36 113.23 124.87
2018-09-30 999.72 646.87 136.68 141.99
2018-06-30 889.63 569.08 122.84 123.64
2018-03-31 876.53 463.43 121.40 128.76
2017-12-31 853.68 387.06 115.97 121.90
2017-09-30 875.02 451.86 121.71 141.82
2017-06-30 848.81 363.93 142.54 168.54
2017-03-31 1,144.15 607.11 137.16 201.11
2016-12-31 1,134.78 689.63 129.90 194.76
2016-09-30 330.32 41.53 89.50 155.98
2016-06-30 330.25 167.76 61.20 143.05
2016-03-31 502.44 383.43 61.62 113.35
2015-12-31 507.24 394.02 58.34 114.74
2015-09-30 511.45 393.30 51.34 141.17
2015-06-30 723.53 551.99 52.94 133.53
2015-03-31 230.97 100.30 39.72 121.53
2014-12-31 228.99 123.59 36.53 114.90
2014-09-30 233.80 135.17 43.43 75.20
2014-06-30 28.10 -127.98 63.78 95.25
2014-03-31 33.75 -116.35 62.31 93.02
2013-12-31 37.40 -117.85 62.74 93.92
2013-09-30 36.90 -109.87 62.02 83.92
2013-06-30 35.86 -105.85 46.26 91.40
2013-03-31 34.90 -97.03 46.81 83.19
2012-12-31 184.03 48.90 46.75 75.42

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • PharmaEngine has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • PharmaEngine used its assets less efficiently than the TW Biotechs industry average last year based on Return on Assets.
  • PharmaEngine's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess PharmaEngine's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
PharmaEngine has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

4162 Health

 How is PharmaEngine's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up PharmaEngine's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • PharmaEngine is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • PharmaEngine's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of PharmaEngine's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • PharmaEngine has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from PharmaEngine Company Filings, last reported 4 months ago.

GTSM:4162 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 3,493.59 0.00 3,588.53
2019-03-31 3,608.93 0.00 3,570.14
2018-12-31 3,694.11 0.00 3,662.86
2018-09-30 3,724.59 0.00 3,685.57
2018-06-30 3,646.59 0.00 3,913.39
2018-03-31 3,866.95 0.00 3,951.23
2017-12-31 3,911.03 0.00 3,278.03
2017-09-30 3,353.82 0.00 3,303.01
2017-06-30 3,355.21 0.00 3,648.87
2017-03-31 3,689.03 0.00 3,757.38
2016-12-31 3,798.78 0.00 3,908.85
2016-09-30 3,175.39 0.00 3,129.05
2016-06-30 3,147.28 0.00 3,357.78
2016-03-31 3,134.63 0.00 3,108.03
2015-12-31 3,159.17 0.00 3,152.30
2015-09-30 3,184.60 0.00 3,180.85
2015-06-30 3,230.24 0.00 3,001.66
2015-03-31 2,903.41 0.00 2,864.41
2014-12-31 2,926.53 0.00 2,898.41
2014-09-30 2,922.91 0.00 2,692.47
2014-06-30 2,687.41 0.00 2,666.42
2014-03-31 2,712.89 0.00 2,684.76
2013-12-31 2,718.09 0.00 2,701.04
2013-09-30 1,825.96 0.00 1,799.07
2013-06-30 1,617.11 0.00 1,589.86
2013-03-31 1,630.42 0.00 1,601.39
2012-12-31 1,636.11 0.00 1,608.95
  • PharmaEngine has no debt.
  • PharmaEngine has not taken on any debt in the past 5 years.
  • PharmaEngine has no debt, it does not need to be covered by operating cash flow.
  • PharmaEngine has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess PharmaEngine's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. PharmaEngine has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

4162 Dividends

 What is PharmaEngine's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.39%
Current annual income from PharmaEngine dividends. Estimated to be 3.7% next year.
If you bought NT$2,000 of PharmaEngine shares you are expected to receive NT$28 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • PharmaEngine's pays a lower dividend yield than the bottom 25% of dividend payers in Taiwan, Province of China (2.59%).
  • PharmaEngine's dividend is below the markets top 25% of dividend payers in Taiwan, Province of China (5.95%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:4162 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1337 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:4162 Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 3.66 1.00
2020-12-31 3.63 1.00
2019-12-31 1.67 2.00
2019-11-11
GTSM:4162 Past Annualized Dividends Data
Date (Data in NT$) Dividend per share (annual) Avg. Yield (%)
2019-03-29 1.000 1.178
2019-03-26 1.000 0.936
2018-03-30 2.000 1.629
2016-03-30 1.389 0.829
2016-03-28 1.389 0.821
2015-03-27 0.694 0.453

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PharmaEngine is not paying a notable dividend for Taiwan, Province of China, therefore no need to check if the payments are stable.
  • PharmaEngine is not paying a notable dividend for Taiwan, Province of China, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of PharmaEngine's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of PharmaEngine's dividends as it is not paying a notable one for Taiwan, Province of China.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2.1x coverage).
X
Income/ dividend checks
We assess PharmaEngine's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can PharmaEngine afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. PharmaEngine has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

4162 Management

 What is the CEO of PharmaEngine's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Hu Yufang
CEO Bio

Dr. Hu Yufang, Ph.D, R.Ph, is President of PharmaEngine, Inc. He is a registered pharmacist as well. Before coming back to Taiwan, he had worked for the Bristol-Myers Squibb Pharmaceutical Company (New Jersey), Barr Laboratory (New Jersey), and the ImmuLogic Pharmaceutical Corporation (Boston). From 1999, he joined TTY Biopharm to build up a R&D Center from scratch, to currently include more than 60 scientists. More than 30 prescription drugs were launched through this center, including two liposomal injections. In addition, another two liposomal injections, and more four long-active depot injection products are presently under development. He has solicited and received substantial government grants for more than 3 million USD to support these two special drug delivery systems: liposome and depot injection plate forms. In 2017, he founded EnhanX Biopharm, Inc., a TTY subsidiary company, that focuses on developing special drug delivery systems. He received his B.S. in Pharmacy from Kaohsiung Medical University in Kaohsiung City, and his M.S. degrees and Ph.D. in Industrial Pharmacy from St. John’s University in New York City.

CEO Compensation
  • Insufficient data for Hu to compare compensation growth.
  • Insufficient data for Hu to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team Tenure

Average tenure of the PharmaEngine management team in years:

4.8
Average Tenure
  • The tenure for the PharmaEngine management team is about average.
Management Team

Grace Yeh

TITLE
Founder & Director
COMPENSATION
NT$20M
TENURE
16.8 yrs

C. Chang

TITLE
Vice President of Finance & Administration
COMPENSATION
NT$5M
TENURE
5.8 yrs

C. Chan

TITLE
Vice President of Clinical & Regulatory Affairs
COMPENSATION
NT$8M
TENURE
3.8 yrs

Hu Yufang

TITLE
President

Alain Herrera

TITLE
Head of Corporate Development & Member of Scientific Advisory Board
AGE
69

Peter Wu

TITLE
Senior Director of Marketing & Sales
TENURE
3.8 yrs

Melody Lin

TITLE
Associate Director of Human Resources

Aimery de Gramont

TITLE
Member of Scientific Advisory Board
Board of Directors Tenure

Average tenure of the PharmaEngine board of directors in years:

3.4
Average Tenure
  • The tenure for the PharmaEngine board of directors is about average.
Board of Directors

Jeffrey Suen

TITLE
Chairman
COMPENSATION
NT$6M
TENURE
4.1 yrs

Grace Yeh

TITLE
Founder & Director
COMPENSATION
NT$20M
TENURE
3.4 yrs

Alain Herrera

TITLE
Head of Corporate Development & Member of Scientific Advisory Board
AGE
69
TENURE
11 yrs

Aimery de Gramont

TITLE
Member of Scientific Advisory Board
TENURE
7.8 yrs

Lin Jin-rong

TITLE
Director
COMPENSATION
NT$62K
TENURE
1.8 yrs

C. Wang

TITLE
Member of the Clinical Advisory Board

Chen Li-Tzong

TITLE
Member of the Scientific Advisory Board

R. Hsieh

TITLE
Member of the Clinical Advisory Board

Eric Raymond

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs

Rui-Wen Wu

TITLE
Director
COMPENSATION
NT$62K
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess PharmaEngine's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. PharmaEngine has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

4162 News

Simply Wall St News

4162 Company Info

Description

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs to treat cancer diseases in Taiwan. The company is developing ONIVYDE for patients with gemcitabine-treated metastatic pancreatic cancer; PEP503, a radio-enhancer, which is in clinical study stage for soft tissue sarcoma, and phase I/II study stage for rectal cancer and head and neck cancer; and PEP06 for cancer treatment in preclinical development stage. PharmaEngine, Inc. was founded in 2003 and is based in Taipei, Taiwan.

Details
Name: PharmaEngine, Inc.
4162
Exchange: GTSM
Founded: 2003
NT$10,516,012,428
146,666,840
Website: http://www.pharmaengine.com
Address: PharmaEngine, Inc.
10 Minsheng East Road,
11th Floor,
Taipei,
104,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 4162 Common Stock Taipei Exchange TW TWD 01. Sep 2011
Number of employees
Current staff
Staff numbers
0
PharmaEngine employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/11 15:00
End of day share price update: 2019/11/11 00:00
Last estimates confirmation: 2019/11/04
Last earnings filing: 2019/08/13
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.